In line with these recent findings, agents that can simultaneously activate GLP-1 and glucagon receptors (so-called dual agonists) are currently undergoing clinical trials as potential novel drugs for the treatment of T2D and related metabolic disorders (12, 13). The gene discussed is GCG; the disease is metabolic disease.